Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16976217 | 1.00 | LMNA (0.57) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| SCHEMBL29173166 | 1.00 | LMNA (0.57) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| Hydrochloric Acid SCHEMBL1311458 | 0.98 | LMNA (0.55) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| SCHEMBL8228203 | 0.87 | LMNA (0.55) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| SCHEMBL14898399 | 0.87 | LMNA (0.55) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| SCHEMBL7368328 | 0.85 | LMNA (0.53) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| SCHEMBL25583339 | 0.85 | BLM (0.59) | LMNACYP2D6SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL11495672 | 0.85 | SMN1; SMN2 (0.50) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| SCHEMBL11495669 | 0.85 | SMN1; SMN2 (0.50) | LMNACYP2D6SMN1; SMN2HIF1ACYP3A4 | |
| SCHEMBL31195757 | 0.84 | HPGD (0.45) | LMNACYP2D6SMN1; SMN2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-20230293638-A1 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | ELI LILLY AND COMPANY | 2023-09-21 | — | — | US | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4056580-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-14 | — | — | EP | disclosed |
| CN-114599389-A | Variant FC domains and uses thereof | 奇达拉治疗公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2019164987-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEATTLE GENETICS, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | LMNA 2924/4885CYP2D6 4794/4885SMN1; SMN2 2268/4885 |
| US-20230293638-A1 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | GLP1R, GIPR, GCGR | LMNA 4840/4885CYP2D6 2509/4885SMN1; SMN2 3497/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | LMNA 2924/4885CYP2D6 4794/4885SMN1; SMN2 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.